Corresponding Author: David S. Knopman, MD, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (knopman@mayo.edu).
Financial Disclosures: Dr Knopman reported serving on a data and safety monitoring board for Sanofi-Aventis Pharmaceuticals (completed October 2008) and receiving personal compensation. He will serve on a data and safety monitoring board for Lilly and will receive personal compensation. Dr Knopman reported being an investigator for clinical trials sponsored by Baxter Pharmaceuticals, Elan Pharmaceuticals, and Forest Pharmaceuticals. He is an associate editor of Neurology for which he receives compensation from the American Academy of Neurology. He also reported serving as a one-time consultant to GlaxoSmithKline regarding an anti-Alzheimer drug.
Funding/Support: This work was supported by grants U01 AG 06786 (Mayo Alzheimer's Disease Patient Registry), P50 AG 16574 (Mayo Alzheimer's Disease Research Center) from the National Institute on Aging, and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program.
Role of the Sponsors: The funding sponsors had no role in the preparation, review, or approval of the editorial.
Editorials represent the opinions of the authors and JAMA and not those of the American Medical Association.